Drug intelligence / Profile preview

MVX-505

Development stage: Unknown
Lead developer: MaveriX Oncology
Modality: Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Intravenous

Overview

MVX-505 is a conditionally activated small-molecule drug conjugate (CA-SMDC) developed by MaveriX Oncology for the treatment of multiple solid tumors. It is designed to selectively deliver a nucleoside phosphate or nucleoside analog cytotoxic payload within the tumor microenvironment, aiming to maximize therapeutic efficacy while minimizing systemic toxicity. The drug is administered intravenously on a weekly schedule. As of early 2025, MVX-505 is entering Phase 1a dose-escalation clinical trials to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.

Targets

DNA

Beyond the preview

Go deeper on MVX-505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVX-505.

Explore the full profile